# HCA Healthcare, Inc.: financial statements, quarterly

HCA · NYSE · CIK 860730 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hca.md) · [Financials](/companies/hca/financials.md) · [Filings](/companies/hca/filings.md) · [Insiders](/companies/hca/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hca/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [17.3 d](/filings/0001193125-26-044769.md) | [17.3](/filings/0000950170-25-061895.md) | [17.5](/filings/0000950170-25-102056.md) | [17.5](/filings/0001193125-25-258667.md) | [18.3 d](/filings/0001193125-26-044769.md) | [18.3](/filings/0001193125-26-191444.md) | [18.6](/filings/0001193125-26-321077.md) | [19.2](/filings/0001193125-26-437871.md) | [19.5 d](/filings/0001193125-26-044769.md) | [19.1](/filings/0001193125-26-191444.md) | [20.2](/filings/0001193125-26-321077.md) | [19.8](/filings/0001193125-26-437871.md) |
| Interest expense | $bn | [0.5 d](/filings/0001193125-26-044769.md) | [0.5](/filings/0000950170-25-061895.md) | [0.5](/filings/0000950170-25-102056.md) | [0.5](/filings/0001193125-25-258667.md) | [0.5 d](/filings/0001193125-26-044769.md) | [0.5](/filings/0001193125-26-191444.md) | [0.6](/filings/0001193125-26-321077.md) | [0.6](/filings/0001193125-26-437871.md) | [0.6 d](/filings/0001193125-26-044769.md) | [0.6](/filings/0001193125-26-191444.md) | [0.6](/filings/0001193125-26-321077.md) | [0.6](/filings/0001193125-26-437871.md) |
| Income tax | $bn | [0.5 d](/filings/0001193125-26-044769.md) | [0.4](/filings/0000950170-25-061895.md) | [0.6](/filings/0000950170-25-102056.md) | [0.4](/filings/0001193125-25-258667.md) | [0.4 d](/filings/0001193125-26-044769.md) | [0.5](/filings/0001193125-26-191444.md) | [0.5](/filings/0001193125-26-321077.md) | [0.5](/filings/0001193125-26-437871.md) | [0.5 d](/filings/0001193125-26-044769.md) | [0.4](/filings/0001193125-26-191444.md) | [0.6](/filings/0001193125-26-321077.md) | [0.5](/filings/0001193125-26-437871.md) |
| Net income | $bn | [1.6 d](/filings/0001193125-26-044769.md) | [1.6](/filings/0000950170-25-061895.md) | [1.5](/filings/0000950170-25-102056.md) | [1.3](/filings/0001193125-25-258667.md) | [1.4 d](/filings/0001193125-26-044769.md) | [1.6](/filings/0001193125-26-191444.md) | [1.7](/filings/0001193125-26-321077.md) | [1.6](/filings/0001193125-26-437871.md) | [1.9 d](/filings/0001193125-26-044769.md) | [1.6](/filings/0001193125-26-191444.md) | [1.7](/filings/0001193125-26-321077.md) | [1.6](/filings/0001193125-26-437871.md) |
| Diluted EPS | $ per share | not reported | [5.93](/filings/0000950170-25-061895.md) | [5.53](/filings/0000950170-25-102056.md) | [4.88](/filings/0001193125-25-258667.md) | not reported | [6.45](/filings/0001193125-26-191444.md) | [6.83](/filings/0001193125-26-321077.md) | [6.96](/filings/0001193125-26-437871.md) | not reported | [7.15](/filings/0001193125-26-191444.md) | [7.62](/filings/0001193125-26-321077.md) | [7.27](/filings/0001193125-26-437871.md) |
| Basic EPS | $ per share | not reported | [6.01](/filings/0000950170-25-061895.md) | [5.60](/filings/0000950170-25-102056.md) | [4.94](/filings/0001193125-25-258667.md) | not reported | [6.52](/filings/0001193125-26-191444.md) | [6.91](/filings/0001193125-26-321077.md) | [7.05](/filings/0001193125-26-437871.md) | not reported | [7.25](/filings/0001193125-26-191444.md) | [7.70](/filings/0001193125-26-321077.md) | [7.36](/filings/0001193125-26-437871.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.9](/filings/0000950170-25-020134.md) | [1.3](/filings/0000950170-24-052195.md) | [0.8](/filings/0000950170-24-087322.md) | [2.9](/filings/0000950170-24-119581.md) | [1.9](/filings/0001193125-26-044769.md) | [1.1](/filings/0000950170-25-061895.md) | [0.9](/filings/0000950170-25-102056.md) | [1.0](/filings/0001193125-25-258667.md) | [1.0](/filings/0001193125-26-437871.md) | [0.9](/filings/0001193125-26-191444.md) | [1.0](/filings/0001193125-26-321077.md) | [0.9](/filings/0001193125-26-437871.md) |
| Current assets | $bn | [14.9](/filings/0000950170-25-020134.md) | [15.3](/filings/0000950170-24-052195.md) | [15.2](/filings/0000950170-24-087322.md) | [16.7](/filings/0000950170-24-119581.md) | [16.4](/filings/0001193125-26-044769.md) | [16.3](/filings/0000950170-25-061895.md) | [15.6](/filings/0000950170-25-102056.md) | [15.3](/filings/0001193125-25-258667.md) | [15.8](/filings/0001193125-26-437871.md) | [16.1](/filings/0001193125-26-191444.md) | [17.2](/filings/0001193125-26-321077.md) | [16.2](/filings/0001193125-26-437871.md) |
| Total assets | $bn | [56.2](/filings/0001193125-26-044769.md) | [57.0](/filings/0000950170-24-052195.md) | [57.4](/filings/0000950170-24-087322.md) | [59.5](/filings/0000950170-24-119581.md) | [59.5](/filings/0001193125-26-044769.md) | [59.8](/filings/0000950170-25-061895.md) | [59.5](/filings/0000950170-25-102056.md) | [59.7](/filings/0001193125-25-258667.md) | [60.7](/filings/0001193125-26-437871.md) | [61.5](/filings/0001193125-26-191444.md) | [63.3](/filings/0001193125-26-321077.md) | [63.5](/filings/0001193125-26-437871.md) |
| Current liabilities | $bn | [12.7](/filings/0000950170-25-020134.md) | [13.1](/filings/0000950170-24-052195.md) | [14.3](/filings/0000950170-24-087322.md) | [14.9](/filings/0000950170-24-119581.md) | [15.2](/filings/0001193125-26-044769.md) | [13.6](/filings/0000950170-25-061895.md) | [15.9](/filings/0000950170-25-102056.md) | [17.9](/filings/0001193125-25-258667.md) | [16.4](/filings/0001193125-26-437871.md) | [19.3](/filings/0001193125-26-191444.md) | [17.3](/filings/0001193125-26-321077.md) | [19.8](/filings/0001193125-26-437871.md) |
| Total liabilities | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $bn | [37.2](/filings/0000950170-25-020134.md) | [37.2](/filings/0000950170-24-052195.md) | [36.3](/filings/0000950170-24-087322.md) | [38.3](/filings/0000950170-24-119581.md) | [38.3](/filings/0001193125-26-044769.md) | [41.1](/filings/0000950170-25-061895.md) | [39.4](/filings/0000950170-25-102056.md) | [38.4](/filings/0001193125-25-258667.md) | [41.6](/filings/0001193125-26-437871.md) | [39.5](/filings/0001193125-26-191444.md) | [43.5](/filings/0001193125-26-321077.md) | [42.4](/filings/0001193125-26-437871.md) |
| Current portion of debt | $bn | [2.4](/filings/0000950170-25-020134.md) | [3.0](/filings/0000950170-24-052195.md) | [4.6](/filings/0000950170-24-087322.md) | [4.7](/filings/0000950170-24-119581.md) | [4.7](/filings/0000950170-25-061895.md) | [3.5](/filings/0000950170-25-061895.md) | [5.1](/filings/0000950170-25-102056.md) | [6.1](/filings/0001193125-25-258667.md) | [4.9](/filings/0001193125-26-437871.md) | [8.5](/filings/0001193125-26-191444.md) | [6.3](/filings/0001193125-26-321077.md) | [8.1](/filings/0001193125-26-437871.md) |
| Shareholders' equity | $bn | [(1.8)](/filings/0000950170-25-020134.md) | [(1.6)](/filings/0000950170-24-052195.md) | [(1.6)](/filings/0000950170-24-087322.md) | [(2.2)](/filings/0000950170-24-119581.md) | [(2.5)](/filings/0001193125-26-044769.md) | [(3.5)](/filings/0000950170-25-061895.md) | [(4.4)](/filings/0000950170-25-102056.md) | [(5.3)](/filings/0001193125-25-258667.md) | [(6.0)](/filings/0001193125-26-437871.md) | [(6.3)](/filings/0001193125-26-191444.md) | [(6.6)](/filings/0001193125-26-321077.md) | [(8.1)](/filings/0001193125-26-437871.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2,674 d](/filings/0001193125-26-044769.md) | [2,469](/filings/0000950170-25-061895.md) | [1,971 d](/filings/0000950170-25-102056.md) | [3,515 d](/filings/0001193125-25-258667.md) | [2,559 d](/filings/0001193125-26-044769.md) | [1,651](/filings/0001193125-26-191444.md) | [4,210 d](/filings/0001193125-26-321077.md) | [4,416 d](/filings/0001193125-26-437871.md) | [2,359 d](/filings/0001193125-26-044769.md) | [2,014](/filings/0001193125-26-191444.md) | [2,335 d](/filings/0001193125-26-321077.md) | [4,461 d](/filings/0001193125-26-437871.md) |
| Capital expenditure | $m | [1,159 d](/filings/0001193125-26-044769.md) | [1,118](/filings/0000950170-25-061895.md) | [1,281 d](/filings/0000950170-25-102056.md) | [1,191 d](/filings/0001193125-25-258667.md) | [1,285 d](/filings/0001193125-26-044769.md) | [991](/filings/0001193125-26-191444.md) | [1,176 d](/filings/0001193125-26-321077.md) | [1,288 d](/filings/0001193125-26-437871.md) | [1,489 d](/filings/0001193125-26-044769.md) | [1,119](/filings/0001193125-26-191444.md) | [1,231 d](/filings/0001193125-26-321077.md) | [1,357 d](/filings/0001193125-26-437871.md) |
| Dividends paid | $m | [160 d](/filings/0001193125-26-044769.md) | [185](/filings/0000950170-25-061895.md) | [171 d](/filings/0000950170-25-102056.md) | [169 d](/filings/0001193125-25-258667.md) | [165 d](/filings/0001193125-26-044769.md) | [180](/filings/0001193125-26-191444.md) | [171 d](/filings/0001193125-26-321077.md) | [166 d](/filings/0001193125-26-437871.md) | [162 d](/filings/0001193125-26-044769.md) | [183](/filings/0001193125-26-191444.md) | [171 d](/filings/0001193125-26-321077.md) | [165 d](/filings/0001193125-26-437871.md) |
| Share repurchases | $m | [910 d](/filings/0001193125-26-044769.md) | [1,180](/filings/0000950170-25-061895.md) | [1,367 d](/filings/0000950170-25-102056.md) | [1,795 d](/filings/0001193125-25-258667.md) | [1,700 d](/filings/0001193125-26-044769.md) | [2,506](/filings/0001193125-26-191444.md) | [2,505 d](/filings/0001193125-26-321077.md) | [2,498 d](/filings/0001193125-26-437871.md) | [2,558 d](/filings/0001193125-26-044769.md) | [1,571](/filings/0001193125-26-191444.md) | [2,064 d](/filings/0001193125-26-321077.md) | [2,970 d](/filings/0001193125-26-437871.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [281](/filings/0000950170-24-052195.md) | [278](/filings/0000950170-24-087322.md) | [275](/filings/0000950170-24-119581.md) | [268](/filings/0000950170-25-061895.md) | [264](/filings/0000950170-25-102056.md) | [260](/filings/0001193125-25-258667.md) | [249](/filings/0001193125-26-191444.md) | [242](/filings/0001193125-26-321077.md) | [236](/filings/0001193125-26-437871.md) | [227](/filings/0001193125-26-191444.md) | [223](/filings/0001193125-26-321077.md) | [217](/filings/0001193125-26-437871.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 208,892,500 at 2026-10-26, from the cover of the [10-Q filed 2026-10-29](/filings/0001193125-26-437871.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:36 ET. No prices; not investment advice.